Canavan Disease Clinical Trial
Official title:
A Natural History Study of Canavan Disease: MGH Site
The purpose of this study is to learn more about the natural history of Canavan disease
For this study, families of subjects will fill out a Canavan Patient Survey which asks
questions about disease development, symptoms and progression. Patients will be seen in Dr.
Eichler's Leukodystrophy clinic for standard of care appointments. These appointments will be
scheduled every 6 months.
The investigators will also collect MRI images and reports that have already been done or
which will be done during participation in the study on a clinical basis.
GLOBAL UNIQUE IDENTIFIERS (GUID):
A patient Global Unique Identifier (GUID) will be used as the identifier for individuals
participating in the study in NeuroBANK™. The GUID is an 11-character string that is
generated using encryption technology and algorithms licensed by the NCRI from the National
Institutes of Health (NIH).
The GUID is generated on a secure website that utilizes 128-bit Secure Socket Layer (SSL). Of
note, this website is not linked to NeuroBANK™. The GUID is generated using an irreversible
encryption algorithm - it accepts twelve identifying data elements, (e.g. last name at birth,
first name at birth, gender at birth, day, month and year of birth, city and country of
birth, etc.), and produces a unique random-generated character string, or GUID. No
identifying information is stored in the system; it is simply used to generate the GUID. If
the same information is entered again, the same GUID will be returned.
The GUID is entered into NeuroBANK™ when the patient is being created in the system. As the
same patient may participate in multiple studies, NeuroBANK™ will also allow capturing a
study-specific ID for the patient. For more information about NeuroBANK™ or the GUID, please
go to: www.neurobank.org.
Data Management:
The NCRI Data Management Team is trained and knowledgeable regarding confidentiality and
integrity of data. They will be responsible for all aspects of data procedures. Alex Sherman
is the ALD Connect network strategist and member of the NEALS ALS consortium. He is the
director of Strategic Development and Systems of NCRI, serves on the Executive Committee of
the ALS Research Group, and is one of the leaders of the NEALS ALS Consortium.
Data Quality Checks, Logic Checks and Queries:
The Data Manager (DM) at the Neurological Clinical Research Institute (NCRI) at the
Massachusetts General Hospital will conduct monthly Data Quality Checks, Logic Checks, and
internal data quality audits. Data field queries will be resolved in an established workflow
according to the Standard Operating Procedures (SOPs). The queries may be created either at
the point of entry during the data entry process, manually by the NCRI DM, or as the result
of executing monthly Logic Checks.
Study-Specific Database Backup and Maintenance:
The NCRI personnel will be responsible for the database backups that will be conducted daily.
Simultaneously, a separate copy of the backup in the encrypted compressed format will be
maintained and saved by the System Analysts. The backups will be saved on a separate computer
partition in a password-protected compressed format and also will be burnt into DVD medium
and stored in a secure location.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04998396 -
A Study of AAV9 Gene Therapy in Participants With Canavan Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00657748 -
Lithium and Acetate for Canavan Disease
|
Phase 2 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT04126005 -
Natural History Study of Patients With Canavan Disease
|
||
Recruiting |
NCT00724802 -
Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
|
N/A | |
Completed |
NCT01999257 -
Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.
|
N/A | |
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Recruiting |
NCT04833907 -
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
|
Phase 1/Phase 2 | |
No longer available |
NCT05317780 -
Canavan-Single Patient IND
|